Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 174

Results For "disease"

2362 News Found

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
Drug Approval | March 29, 2022

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults


Dupixent is a star in Sanofi’s immunology strategy
Biotech | March 29, 2022

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion


USFDA clears IND application for an intranasal RSV vaccine
Biotech | March 29, 2022

USFDA clears IND application for an intranasal RSV vaccine

The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers


Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool
Medical Device | March 29, 2022

Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool

Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products


Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
Drug Approval | March 28, 2022

Tarlige tablets approved in Japan for treatment of patients with neuropathic pain

In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP


NTT DATA launches hackathon for AI innovations in healthcare
Digitisation | March 28, 2022

NTT DATA launches hackathon for AI innovations in healthcare

Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes


New spesolimab data show promising results in patients with generalised pustular psoriasis flares
Biotech | March 28, 2022

New spesolimab data show promising results in patients with generalised pustular psoriasis flares

Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status


Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis
Biotech | March 27, 2022

Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis

There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022


NMPA approves Hansizhuang, its first monoclonal antibody
Drug Approval | March 27, 2022

NMPA approves Hansizhuang, its first monoclonal antibody

It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry


ScienceMedia and Apex Mobile Clinical Research sign partnership for clinical trial training
Biotech | March 27, 2022

ScienceMedia and Apex Mobile Clinical Research sign partnership for clinical trial training

The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment